Treatment Archives – Page 4 of 11 – Treatment Action Group

TB Treatment Trial Results in Context for Communities

February 17, 2023
Dorrit Walsh

On Tuesday, March 14 at 8:00 am ET, join Treatment Action Group (TAG) and Dr. Jennifer Furin for an overview of key results and breakdown of how they fit into the larger TB policy and research landscapes.

Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health

November 16, 2022
Dorrit Walsh

Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.

Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens

October 27, 2022
Dorrit Walsh

As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.

Storytelling to Support TB Preventive Treatment (TPT)

October 24, 2022
Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…

Treatment Action Group Statement: U.S. District Court Ruling Allowing Employers to Deny PrEP Coverage Is a Dangerous Attack on Public Health

October 6, 2022
Dorrit Walsh

Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

August 1, 2022
Dorrit Walsh

We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City

May 16, 2022
Dorrit Walsh

We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB).

Test and Treat COVID-19: Community Guide to Molnupiravir

April 20, 2022
Dorrit Walsh

This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs.

cover of: Test and Treat Mild or Moderate COVID-19: Paxlovid (nirmatrelvir/ritonavir)

Test and Treat COVID-19: Community Guide to Paxlovid

April 11, 2022
Dorrit Walsh

Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is,…

HIV Updates From CROI: The Good, the Bad, and the Long-Acting

March 29, 2022
Dorrit Walsh

On April 15 TAG presented, "HIV Updates From CROI: The Good, the Bad, and the Long-Acting." This free webinar unpacked the most significant developments in HIV research presented at the Conference on Retroviruses and Opportunistic Infection (CROI), and what they mean for communities affected by HIV.